Discovery of novel osthole derivatives as potential anti-breast cancer treatment

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7426-8. doi: 10.1016/j.bmcl.2010.10.027. Epub 2010 Nov 2.

Abstract

Osthole, an ingredient of Traditional Chinese Medicine (TCM) from natural product Cnidium monnieri (L.) Cusson, was used as a lead compound for structural modification. A series of osthole derivatives bearing aryl substituents at 3-position of coumarin, has been prepared and evaluated for their growth inhibitory activity against human breast cancer cell lines MCF-7 and MDA-MB-231. Interestingly, some derivatives exhibited good inhibition, among them compound 8e was found to be the most potent compound with IC(50) values of 0.24 μM, 0.31 μM against MCF-7 and MDA-MB-231, respectively, which was improved more than 100-folds compared with its parent compound osthole.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Cell Line, Tumor
  • Cnidium / chemistry
  • Coumarins / chemical synthesis
  • Coumarins / chemistry*
  • Coumarins / therapeutic use
  • Female
  • Humans

Substances

  • Antineoplastic Agents
  • Coumarins
  • coumarin
  • osthol